EUVIMEDEUVIMED entdecken
Crossref

Plasma anti-FDX1 autoantibody as a potential biomarker for detection and diagnosis of breast cancer

Fangfang Liu, Yunhui Qu, Peiqi Yu, Jingjing Liu

Clinical Immunology · 2026-06 · 285 · 110697

DOI: 10.1016/j.clim.2026.110697 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Immunology, 2026-06. Verfasst von Fangfang Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Medical Education, Puyang Medical College, 457000 Puyang, China; Henan Institute of Medical and Pharmaceutical Sciences, Zhengzho…. Hauptthemen laut MEDLINE: Autoantibodies, Breast Neoplasms, Biomarkers, Tumor. Die Arbeit nennt 39 Literaturangaben. Gefördert von: Hainan Association for Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autoantibodies have emerged as highly valuable biomarkers for cancer detection. Ferredoxin 1 (FDX1), a key cuproptosis regulator, significantly influences breast cancer prognosis. This study aimed to investigate whether the anti-FDX1 autoantibody can serve as a novel biomarker for breast cancer detection and diagnosis. Anti-FDX1 levels were detected in plasma from 336 breast cancer patients (BC), 220 patients with benign breast nodule (BBN), and 236 normal controls (NC) using ELISA assay. Anti-FDX1 levels in BC were lower than that in NC and BBN. Subgroup analysis revealed enhanced diagnostic efficacy in Luminal A patients aged

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AutoantibodiesBreast NeoplasmsBiomarkers, TumorHumansFemaleMiddle AgedAdultAged

Stichwörter der Autor:innen

Anti-FDX1 autoantibodyBreast cancerCombined modelsScreening and diagnosis

Substanzen

AutoantibodiesBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Basic Medical Education, Puyang Medical College, 457000 Puyang, China; Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, 450052 Zhengzhou, China.
  • Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, 450052 Zhengzhou, China.
  • Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, 450052 Zhengzhou, China.
  • Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, 450052 Zhengzhou, China. Electronic address: ljj903@hotmail.com.

Förderung

  • Hainan Association for Science and Technology

Zitieren

APA

Liu, F., Qu, Y., Yu, P., & Liu, J. (2026). Plasma anti-FDX1 autoantibody as a potential biomarker for detection and diagnosis of breast cancer. Clinical Immunology, 285, 110697. https://doi.org/10.1016/j.clim.2026.110697

Vancouver

Liu F, Qu Y, Yu P, Liu J. Plasma anti-FDX1 autoantibody as a potential biomarker for detection and diagnosis of breast cancer. Clinical Immunology. 2026;285:110697. doi:10.1016/j.clim.2026.110697

BibTeX
@article{Liu2026,
  author = {Liu, Fangfang and Qu, Yunhui and Yu, Peiqi and Liu, Jingjing},
  title = {Plasma anti-FDX1 autoantibody as a potential biomarker for detection and diagnosis of breast cancer},
  journal = {Clinical Immunology},
  year = {2026},
  volume = {285},
  pages = {110697},
  doi = {10.1016/j.clim.2026.110697}
}
Kostenlos starten →